Please share...
NEW YORK/WASHINGTON (Reuters) – Mylan NV’s price hikes on EpiPens have added millions to U.S. Department of Defense spending since 2008 as the agency covered more prescriptions for the lifesaving allergy shot at near retail prices, government data provided to Reuters shows.
